The French Society of Clinical Biology (SFBC) set up a working group “Biochemical markers of Covid-19” whose main objective is to review, analyse and monitor biological prescriptions according to the patient’s care path. This study covers all public and private sectors of medical biology in metropolitan France and overseas and extends to the French-speaking world. We present a summary of feedbacks after 2 years of the pandemic. At the early stage of Covid-19, with regard to the regions surveyed, a common symptomatology with local zoonosis (dengue fever, zika, malaria, leptospirosis, etc.) complicates the diagnosis of Covid-19. At a more advanced stage, it is a question of managing an influx of patients suffering from acute respiratory distress syndrome. In this case, the biology is then simpler and delocalized medical biology devices have proven their effectiveness. As a result, ICU clinicians can better manage the frequent comorbidities encountered in these regions: obesity, diabetes, chronic renal failure, cardiovascular diseases.
【저자키워드】 COVID-19, acute respiratory distress syndrome, overseas territories, French-speaking countries, medical biology, ARDS.,